DEMADEX by Roche is clinical pharmacology mechanism of action micropuncture studies in animals have shown that torsemide acts from within the lumen of the thick ascending portion of the loop of henle, where it inhibits the na/k/2ci-carrier system. Approved for edema associated with congestive heart failure, renal disease, hepatic disease and 2 more indications. First approved in 1993.
Drug data last refreshed 9h ago · AI intelligence enriched 6d ago
DEMADEX (torsemide) is a loop diuretic administered intravenously that inhibits the Na/K/2Cl-carrier system in the thick ascending loop of Henle, increasing urinary excretion of sodium, chloride, and water. It is indicated for edema associated with congestive heart failure, renal disease, hepatic disease, and hypertension, either alone or in combination with other antihypertensive agents. The drug's diuretic activity correlates with urinary excretion rate rather than serum concentration.
Product approaching loss of exclusivity with limited commercial expansion opportunity; team restructuring likely imminent.
CLINICAL PHARMACOLOGY Mechanism of Action Micropuncture studies in animals have shown that torsemide acts from within the lumen of the thick ascending portion of the loop of Henle, where it inhibits the Na/K/2CI-carrier system. Clinical pharmacology studies have confirmed this site of action in…
Worked on DEMADEX at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on DEMADEX offers limited career growth opportunity given its LOE-approaching status and minimal linked job openings; positions are primarily defensive brand management focused on revenue protection and generic transition planning. Career advancement is constrained by lack of expansion indications, clinical development, and commercial scaling.